摘要
目的考察吴茱萸-姜黄素碱纳米粒(evodiamine-curcumin nanoparticles,ECNP)在大鼠体内的药动学特征,探讨姜黄素(CUR)对吴茱萸碱(EVO)生物利用度的影响。方法采用溶剂挥发法制备ECNP,大鼠分别ig给予ECNP、吴茱萸碱姜黄素混合物(MEC)、EVO后,在不同时间点于眼底静脉采血,采用HPLC法测定血浆中EVO的质量浓度。结果 ECNP、MEC和游离EVO组EVO的AUC_(0~t)分别为(3 197.74±81.64)、(1 387.73±39.42)、(928.08±54.84)μg·h/L。其中,MEC组的AUC_(0~t)为游离EVO组的1.50倍;ECNP组的AUC_(0~t)分别为游离EVO组和MEC组的3.45倍和2.30倍。结论 CUR与EVO配伍能促进EVO的口服吸收,制备成纳米粒制剂后进一步提高EVO在大鼠体内的口服生物利用度。
Objective To investigate the in vivo pharmacokinetic characteristics of evodiamine-curcumin nanoparticles（ECNP）, and to discuss the influence of curcumin（CUR） to the bioavailability of evodiamine（EVO）. Methods ECNP were prepared by solvent evaporation method. Rats were orally given ECNP. After administration, blood samples were collected from the retinal venous plexus of SD rats at different time points. And the blood concentration of EVO was determined by HPLC. Results The AUC_（0-t） of ECNP, mixture of evodiamine and curcumin（MEC） and free EVO were（3 197.74 ± 81.64） μg·h/L,（1 387.73 ± 39.42） μg·h/L, and（928.08 ± 54.84） μg·h/L, respectively. The AUC_（0-t） of MEC was 1.50 times as free EVO. The AUC_（0-t） of ECNP was 3.45 and 2.30 times as EVO and MEC, respectively. Conclusion The absorption of EVO in rats was promoted with CUR, and nanoparticles can further improve the oral bioavailability of EVO in rats.
出处
《中草药》
CAS
CSCD
北大核心
2017年第14期2902-2906,共5页
Chinese Traditional and Herbal Drugs
基金
重庆市科委资助项目(csct2015jcyjBX0027)
关键词
吴茱萸碱
姜黄素
纳米粒
药动学
生物利用度
evodiamine
curcumin
nanoparticle
pharmacokinetics
bioavailability
作者简介
余忠姝（1991-），女，在读硕士，研究方向为药物分析。E-mail：792916952@qq．com
通信作者赵华（1965～），女，教授，硕士研究生导师，研究方向体内药物分析及其代谢。Tel：13390884821 E-mail：zhaohua．cq@sohu．com
